JP2001508864A - ペプチドの測定により生物の状態を検出する方法 - Google Patents
ペプチドの測定により生物の状態を検出する方法Info
- Publication number
- JP2001508864A JP2001508864A JP50940798A JP50940798A JP2001508864A JP 2001508864 A JP2001508864 A JP 2001508864A JP 50940798 A JP50940798 A JP 50940798A JP 50940798 A JP50940798 A JP 50940798A JP 2001508864 A JP2001508864 A JP 2001508864A
- Authority
- JP
- Japan
- Prior art keywords
- molecular weight
- organism
- peptide
- low molecular
- measurement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
- Y10T436/255—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.] including use of a solid sorbent, semipermeable membrane, or liquid extraction
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 生物の状態の指標となる高分子量及び低分子量ペプチドを含有する前記生 物のサンプルについてペプチドの測定をすることにより前記生物の状態を検 出する方法であって、 ― 低分子量ペプチドは直接検出され、特徴づけされ、 ― 参照と関連付けられる方法。 2.前記サンプルが前記生物からの組織若しくは流動体、又は生物そのもの、ま たはそれらの組み合せである請求項1に記載の方法。 3.前記測定に使用される前記低分子量ペプチドが30,000ダルトン以下の分子量 を有する請求項1又は2に記載の方法。 4.前記測定に使用する前記低分子量ペプチドが少なくともジペプチドの分子量 に対応する分子量を有する請求項3に記載の方法。 5.前記測定に使用する前記低分子量ペプチドが100から10,000ダルトンの分子 量を有する請求項3及び/又は4に記載の方法。 6.サンプルの記録において、前記高分子量ペプチドを前記低分子量ペプチドの 測定の前に分離するが、又は測定若しくは評価に関して考慮せず残す請求項 1から5の少なくとも1項に記載の方法。 7.前記低分子量ペプチドの検出が質量分析により行われる請求項1から6の少 なくとも1項に記載の方法。 8.前記低分子量ペプチドがそれらの分子量の測定を介して特徴づけられる請求 項1から7の少なくとも1項に記載の方法。 9.前記低分子量ペプチドの測定の前に、前記サンプルを異なるフラクションに 分離し、そのフラクションが異なる条件において測定される請求項1から8 の少なくとも1項に記載の方法。 10. 前記生物が原核生物、真核生物、多細胞生物、組織培養物からの細胞、 動物及び人間の細胞を含む請求項1から9の少なくとも1項に記載の方法。 11. 前記サンプルが遺伝子的に技術改良された又はトランスフォームされた 及び/又はコンディショニングされた生物から誘導される請求項1から10の 少なくとも1項に記載の方法。 12. 生物の状態の検出が、参照状態からの偏差を明らかにするために、仮説 に基づく必要なしに、生物の全体的な状態の検査及び記録のために用いられ る請求項1から11の少なくとも1項に記載の方法。 13. トランスフォームされた生物の状態の検出が、原因として代謝の変化に 関連するトランスフォメーションに関連したペプチドの発生を明らかにする ためのトランスフォームされた生物の変化を明らかにするために、仮説に基 づく必要なしに、生物の全体的な状態の試験及び記録のために用いられる請 求項1から11の少なくとも1項に記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1996132521 DE19632521A1 (de) | 1996-08-13 | 1996-08-13 | Verfahren zur Gewinnung von Peptiden aus Köperflüssigkeiten und Geweben sowie Zellüberständen und zur Identifikation von krankheitsrelevanten Peptidmarkern |
DE19632521.8 | 1997-06-16 | ||
DE19725362.8 | 1997-06-16 | ||
DE19725362 | 1997-06-16 | ||
PCT/EP1997/004396 WO1998007036A1 (de) | 1996-08-13 | 1997-08-13 | Verfahren zur erfassung des status eines organismus durch messung von peptiden |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2001508864A true JP2001508864A (ja) | 2001-07-03 |
Family
ID=26028345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50940798A Ceased JP2001508864A (ja) | 1996-08-13 | 1997-08-13 | ペプチドの測定により生物の状態を検出する方法 |
Country Status (16)
Country | Link |
---|---|
US (1) | US6875616B1 (ja) |
EP (1) | EP0922226B2 (ja) |
JP (1) | JP2001508864A (ja) |
CN (1) | CN1233326A (ja) |
AT (1) | ATE234469T1 (ja) |
AU (1) | AU720626B2 (ja) |
CA (1) | CA2263443C (ja) |
CZ (1) | CZ294729B6 (ja) |
DE (1) | DE59709517D1 (ja) |
DK (1) | DK0922226T3 (ja) |
EA (1) | EA001033B1 (ja) |
ES (1) | ES2191175T3 (ja) |
IS (1) | IS4971A (ja) |
PL (1) | PL186810B1 (ja) |
PT (1) | PT922226E (ja) |
WO (1) | WO1998007036A1 (ja) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6936424B1 (en) | 1999-11-16 | 2005-08-30 | Matritech, Inc. | Materials and methods for detection and treatment of breast cancer |
DE10021737C2 (de) * | 2000-05-04 | 2002-10-17 | Hermann Haller | Verfahren und Vorrichtung zur qualitativen und/oder quantitativen Bestimmung eines Protein- und/oder Peptidmusters einer Flüssigkeitsprobe, die dem menschlichen oder tierischen Körper entnommen wird |
US20020160533A1 (en) | 2001-04-30 | 2002-10-31 | George Jackowski | Biopolymer marker indicative of disease state having a molecular of weight of 1525 daltons |
US6593298B2 (en) | 2001-04-30 | 2003-07-15 | Syn X Pharma, Inc. | Biopolymer marker indicative of disease state having a molecular weight of 1690 daltons |
US7314717B2 (en) | 2001-04-30 | 2008-01-01 | Nanogen Inc. | Biopolymer marker indicative of disease state having a molecular weight of 1562 daltons |
US7008800B2 (en) | 2001-04-30 | 2006-03-07 | Artemis Proteomics, Ltd. | Biopolymer marker indicative of disease state having a molecular weight of 1077 daltons |
US6602855B2 (en) | 2001-04-30 | 2003-08-05 | Syn X Pharma, Inc. | Biopolymer marker indicative of disease state having a molecular weight of 1449 daltons |
US6627608B2 (en) | 2001-04-30 | 2003-09-30 | Syn X Pharma, Inc. | Biopolymer marker indicative of disease state having a molecular weight of 1206 daltons |
US7015004B2 (en) | 2001-11-23 | 2006-03-21 | Syn X Pharma, Inc. | Inter-alpha trypsin inhibitor biopolymer marker indicative of insulin resistance |
US6756476B2 (en) | 2001-04-30 | 2004-06-29 | Syn X Pharma, Inc. | Biopolymer marker indicative of disease state having a molecular weight of 2021 daltons |
US6693080B2 (en) | 2001-04-30 | 2004-02-17 | Syn X Pharma | Biopolymer marker indicative of disease state having a molecular weight of 1521 daltons |
US7087435B2 (en) | 2001-04-30 | 2006-08-08 | Syn X Pharma, Inc. | Biopolymer marker indicative of disease state having a molecular weight of 2753 daltons |
US6703366B2 (en) | 2001-04-30 | 2004-03-09 | George Jackowski | Biopolymer marker indicative of disease state having a molecular weight of 1,896 daltons |
US6677303B2 (en) | 2001-04-30 | 2004-01-13 | Syn X Pharma | Biopolymer marker indicative of disease state having a molecular weight of 1097 daltons |
US6599877B2 (en) | 2001-04-30 | 2003-07-29 | Syn X Pharma, Inc. | Biopolymer marker indicative of disease state having a molecular weight of 1020 daltons |
US20020160420A1 (en) * | 2001-04-30 | 2002-10-31 | George Jackowski | Process for diagnosis of physiological conditions by characterization of proteomic materials |
US6627607B2 (en) | 2001-04-30 | 2003-09-30 | Syn X Pharma, Inc. | Biopolymer marker indicative of disease state having a molecular weight of 1845 daltons |
US6890763B2 (en) | 2001-04-30 | 2005-05-10 | Syn X Pharma, Inc. | Biopolymer marker indicative of disease state having a molecular weight of 1350 daltons |
US6627606B2 (en) | 2001-04-30 | 2003-09-30 | Syn X Pharma, Inc. | Biopolymer marker indicative of disease state having a molecular weight of 1465 daltons |
US6617308B2 (en) | 2001-04-30 | 2003-09-09 | Syn X Pharma, Inc. | Biopolymer marker indicative of disease state having a molecular weight of 1865 daltons |
US6620786B2 (en) | 2001-04-30 | 2003-09-16 | Syn X Pharma, Inc. | Biopolymer marker indicative of disease state having molecular weight of 2937 daltons |
US20040198950A1 (en) | 2001-04-30 | 2004-10-07 | George Jackowski | Biopolymer marker indicative of disease state having a molecular weight of 1518 daltons |
US7294688B2 (en) | 2001-04-30 | 2007-11-13 | Nanogen Inc. | Biopolymer marker indicative of disease state having a molecular weight of 1348 daltons |
US6620787B2 (en) | 2001-04-30 | 2003-09-16 | Syn X Pharma, Inc. | Biopolymer marker indicative of disease state having a molecular weight of 2267 daltons |
DE10123711A1 (de) * | 2001-05-15 | 2003-02-27 | Wolfgang Altmeyer | Verfahren zur Bestimmung der Herkunft biologischer Materialien |
US7179610B2 (en) | 2001-11-23 | 2007-02-20 | Nanogen Inc. | Complement C3 precursor biopolymer markers indicative of insulin resistance |
US7314762B2 (en) | 2001-11-21 | 2008-01-01 | Nanogen, Inc. | Apolipoprotein biopolymer markers indicative of insulin resistance |
US7132244B2 (en) | 2001-11-21 | 2006-11-07 | Syn X Pharma, Inc. | Betaine/GABA transport protein biopolymer marker indicative of insulin resistance |
US7052849B2 (en) | 2001-11-23 | 2006-05-30 | Syn X Pharma, Inc. | Protein biopolymer markers predictive of insulin resistance |
US20030100014A1 (en) * | 2001-11-23 | 2003-05-29 | George Jackowski | Apolipoprotein biopolymer markers predictive of type II diabetes |
US7135297B2 (en) | 2001-11-23 | 2006-11-14 | Nanogen Inc. | Protein biopolymer markers indicative of insulin resistance |
WO2003046556A2 (en) * | 2001-11-23 | 2003-06-05 | Syn.X Pharma, Inc. | Globin biopolymer markers indicative of insulin resistance |
US7026129B2 (en) | 2001-11-23 | 2006-04-11 | Syn X Pharma, Inc. | IG lambda biopolymer markers predictive of Alzheimers disease |
US6890722B2 (en) | 2001-11-23 | 2005-05-10 | Syn X Pharma, Inc. | HP biopolymer markers predictive of insulin resistance |
US7074576B2 (en) | 2001-11-23 | 2006-07-11 | Syn X Pharma, Inc. | Protein biopolymer markers indicative of alzheimer's disease |
US7094549B2 (en) | 2001-11-23 | 2006-08-22 | Syn X Pharma, Inc. | Fibronectin biopolymer marker indicative of insulin resistance |
US7122327B2 (en) | 2001-11-23 | 2006-10-17 | Nanogen Inc. | Biopolymer markers indicative of type II diabetes |
US7125678B2 (en) * | 2001-11-23 | 2006-10-24 | Nanogen, Inc. | Protein biopolymer markers predictive of type II diabetes |
US7179606B2 (en) | 2001-11-23 | 2007-02-20 | Syn X Pharma, Inc. | IG heavy chain, IG kappa, IG lambda biopolymer markers predictive of Alzheimer's disease |
US7179605B2 (en) | 2001-11-23 | 2007-02-20 | Nanogen Inc. | Fibronectin precursor biopolymer markers indicative of alzheimer's disease |
US7097989B2 (en) | 2001-11-23 | 2006-08-29 | Syn X Pharma, Inc. | Complement C3 precursor biopolymer markers predictive of type II diabetes |
WO2004089972A2 (en) | 2003-04-02 | 2004-10-21 | Merck & Co., Inc. | Mass spectrometry data analysis techniques |
DE10341193A1 (de) * | 2003-09-06 | 2005-03-31 | Mosaiques Diagnostics And Therapeutics Ag | Vorrichtung und Verfahren zur quantitativen Auswertung der in einer Körperflüssigkeitsprobe enthaltenden Polypeptide sowie Marker zur Erkennung von pathologischen Zuständen |
US20090035797A1 (en) * | 2004-10-15 | 2009-02-05 | Hancock William S | Detection of Disease Associated Proteolysis |
WO2009016431A1 (en) * | 2007-08-01 | 2009-02-05 | Digilab, Inc. | Sample preparation method and apparatus |
US10059975B2 (en) * | 2008-10-31 | 2018-08-28 | Biomerieux, Inc. | Methods for the isolation and identification of microorganisms |
CA2741008C (en) * | 2008-10-31 | 2018-08-28 | Biomerieux, Inc. | Methods for separation and characterization of microorganisms using identifier agents |
US10415075B2 (en) * | 2008-10-31 | 2019-09-17 | Biomerieux, Inc. | Method for separation, characterization and/or identification of microorganisms using mass spectrometry |
WO2013147610A2 (en) | 2012-03-30 | 2013-10-03 | Jetze Botma | Automated selection of microorganisms and identification using maldi |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08500577A (ja) * | 1992-07-15 | 1996-01-23 | ユニヴァーシティ オブ サウス フロリダ | パニック障害の治療に関連するcckペプチドの血中濃度 |
JPH09178740A (ja) * | 1995-10-24 | 1997-07-11 | Tokuyama Corp | 糖尿病または糖尿病合併症用マーカーとしての使用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5537944A (en) * | 1978-09-09 | 1980-03-17 | Seiichi Shibata | Diagnosis chemical and diagnosis method of kidney disease |
US5492834A (en) * | 1993-07-09 | 1996-02-20 | Beckman Instruments, Inc. | Method of sample preparation for urine protein analysis with capillary electrophoresis |
DE4427531A1 (de) * | 1994-08-04 | 1996-02-08 | Forssmann Wolf Georg | Humanes zirkulierendes beta-Defensin hBD-1 |
-
1997
- 1997-08-13 CA CA002263443A patent/CA2263443C/en not_active Expired - Fee Related
- 1997-08-13 PL PL97331612A patent/PL186810B1/pl not_active IP Right Cessation
- 1997-08-13 PT PT97918977T patent/PT922226E/pt unknown
- 1997-08-13 DK DK97918977T patent/DK0922226T3/da active
- 1997-08-13 CZ CZ1999491A patent/CZ294729B6/cs not_active IP Right Cessation
- 1997-08-13 DE DE59709517T patent/DE59709517D1/de not_active Expired - Lifetime
- 1997-08-13 US US09/242,254 patent/US6875616B1/en not_active Expired - Fee Related
- 1997-08-13 AT AT97918977T patent/ATE234469T1/de not_active IP Right Cessation
- 1997-08-13 EP EP97918977A patent/EP0922226B2/de not_active Expired - Lifetime
- 1997-08-13 CN CN97198763A patent/CN1233326A/zh active Pending
- 1997-08-13 EA EA199900196A patent/EA001033B1/ru not_active IP Right Cessation
- 1997-08-13 ES ES97918977T patent/ES2191175T3/es not_active Expired - Lifetime
- 1997-08-13 WO PCT/EP1997/004396 patent/WO1998007036A1/de active IP Right Grant
- 1997-08-13 JP JP50940798A patent/JP2001508864A/ja not_active Ceased
- 1997-08-13 AU AU42988/97A patent/AU720626B2/en not_active Ceased
-
1999
- 1999-02-10 IS IS4971A patent/IS4971A/is unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08500577A (ja) * | 1992-07-15 | 1996-01-23 | ユニヴァーシティ オブ サウス フロリダ | パニック障害の治療に関連するcckペプチドの血中濃度 |
JPH09178740A (ja) * | 1995-10-24 | 1997-07-11 | Tokuyama Corp | 糖尿病または糖尿病合併症用マーカーとしての使用 |
Non-Patent Citations (10)
Title |
---|
JPN6009028355, 小児科診療, 199604, Vol.59 増刊号, Page.231−233 * |
JPN6009028360, 日本マススクリーニング学会誌, 1996, Vol.6, No.1, Page.31−39 * |
JPN6009028363, 新しいスクリーニングのあり方に関する研究 平成7年度研究報告書, 1996, Page.72−75 * |
JPN6009028367, 島津評論, 1996, Vol.53, No.1, Page.35−41 * |
JPN6010008249, J Mass Spectrom, 1995, Vol.30, No.12, Page.1663−1670 * |
JPN6010008252, 日本医用マススペクトル学会講演集, 1994, Vol.19, Page.163−166 * |
JPN6010008254, 日本医用マススペクトル学会講演集, 1993, Vol.18, Page.137−140 * |
JPN6010008257, 日本医用マススペクトル学会講演集, 1994, Vol.19, Page.143−145 * |
JPN6010008260, Biomed Environ Mass Spectrom, 1989, Vol.18, No.9, Page.757−760 * |
JPN6010008264, 日本医用マススペクトル学会講演集, 1990, Vol.15, Page.99−102 * |
Also Published As
Publication number | Publication date |
---|---|
US6875616B1 (en) | 2005-04-05 |
EA001033B1 (ru) | 2000-08-28 |
CN1233326A (zh) | 1999-10-27 |
WO1998007036A1 (de) | 1998-02-19 |
CZ294729B6 (cs) | 2005-03-16 |
EP0922226B2 (de) | 2008-06-25 |
DK0922226T3 (da) | 2003-07-07 |
PL331612A1 (en) | 1999-08-02 |
AU720626B2 (en) | 2000-06-08 |
PL186810B1 (pl) | 2004-02-27 |
DE59709517D1 (de) | 2003-04-17 |
EA199900196A1 (ru) | 1999-06-24 |
EP0922226A1 (de) | 1999-06-16 |
ES2191175T3 (es) | 2003-09-01 |
CZ49199A3 (cs) | 2000-04-12 |
ATE234469T1 (de) | 2003-03-15 |
CA2263443A1 (en) | 1998-02-19 |
AU4298897A (en) | 1998-03-06 |
PT922226E (pt) | 2003-07-31 |
EP0922226B1 (de) | 2003-03-12 |
IS4971A (is) | 1999-02-10 |
CA2263443C (en) | 2004-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001508864A (ja) | ペプチドの測定により生物の状態を検出する方法 | |
JP6672411B2 (ja) | 癌療法を示すためのsrmアッセイ | |
EP2659267B1 (en) | C-met protein srm/mrm assay | |
AU2017201499B2 (en) | Her3 protein SRM/MRM assay | |
AU2015203904B2 (en) | SRM assay for PD-L1 | |
JP2013534315A (ja) | c−Src選択反応モニタリングアッセイ | |
US10718780B2 (en) | SRM/MRM assay for the tyrosine-protein kinase receptor UFO(AXL) protein | |
CN107847866B (zh) | 细胞周期蛋白依赖性激酶抑制剂2A(p16)的SRM/MRM测定 | |
US20190056406A1 (en) | SRM/MRM Assay for the 6-O-methylguanine-DNA methyltransferase (MGMT) protein | |
CN112379008B (zh) | 一种检测红细胞中Prx2蛋白的Asp46外消旋化程度的方法 | |
CN107850605B (zh) | 间皮素(msln)蛋白质的srm/mrm测定 | |
EP3295181A1 (en) | Srm/mrm assay for the fibroblast growth factor receptor 2 (fgfr2) protein | |
KR102014694B1 (ko) | 종양 괴사 인자 수용체 수퍼패밀리 구성원 8(cd30) 단백질에 대한 srm/mrm 검정 | |
JP2008058161A (ja) | 子宮体癌の検出方法 | |
EP0652437A1 (en) | Improved method for determining lipid bound sialic acid in plasma or serum |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040715 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071002 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071226 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080208 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080204 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080310 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080227 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080414 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080401 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080930 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081224 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090209 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090128 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090309 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090225 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090413 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090331 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090616 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090911 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091026 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091016 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091120 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091216 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100223 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20100614 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100810 |